A new meta-analysis reports that intensive blood pressure lowering reduces the risk of kidney failure in patients with chronic kidney disease and albuminuria. However, the level of blood pressure control required for optimum protection of the cardiovascular and renal systems remains unclear.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Medication burden and inappropriate prescription risk among elderly with advanced chronic kidney disease
BMC Geriatrics Open Access 04 March 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Lv, J. et al. Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis. CMAJ 185, 949–957 (2013).
Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. Suppl. 2, 337–414 (2012).
American Diabetes Association. 2013 Clinical Practice Recommendations. Diabetes Care 36 (Suppl. 1), S1–S110 (2013).
Mancia, G. et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). J. Hypertens. 31, 1281–1357 (2013).
Ruilope, L. M. & Bakris, G. L. Renal function and target organ damage in hypertension. Eur. Heart J. 32, 1599–1604 (2011).
Dahlöf, B. et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised control trial. Lancet 366, 895–906 (2005).
De Galan, B. E. et al. Lowering blood pressure reduces renal events in type 2 diabetes. J. Am. Soc. Nephrol. 20, 883–892 (2009).
Jamerson, K. et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high risk patients. N. Engl. J. Med. 359, 2417–2428 (2008).
Parving, H. H. et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N. Engl. J. Med. 367, 2204–2213 (2012).
Gorostidi, M. et al. Differences between office and 24-hour blood pressure control in hypertensive patients with CKD: a 5,693-patient cross-sectional analysis from Spain. Am. J. Kidney Dis. 62, 285–294 (2013).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Ruilope, L. Blood pressure control in CKD—still a matter of debate. Nat Rev Nephrol 9, 572–573 (2013). https://doi.org/10.1038/nrneph.2013.180
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2013.180
This article is cited by
-
Medication burden and inappropriate prescription risk among elderly with advanced chronic kidney disease
BMC Geriatrics (2020)
-
Global cardiovascular protection in chronic kidney disease
Nature Reviews Cardiology (2016)
-
Does cardiovascular protection translate into renal protection?
Nature Reviews Cardiology (2014)